COMPANION-002: CTX-009 + Paclitaxel in Advanced Biliary Tract Cancer

Market
100%75%50%25%0%Apr 26 • YES 36.8%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
7/1/25
Study Completion
12/1/25
Sponsor
Compass Therapeutics
Ticker
$CMPX
Type
Phase 2/Phase 3
Trial Status
Active Not Recruiting
Trial Size
150
NCT
NCT05506943
Trial Description
This is a multicenter, open-label, randomized Phase 2/3 study of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel alone in adults with unresectable advanced, metastatic, or recurrent biliary tract cancers after one prior systemic chemotherapy regimen. The primary endpoint is best overall response by RECIST 1.1.